stoxline Quote Chart Rank Option Currency Glossary
  
GlycoMimetics, Inc. (GLYC)
3  -0.18 (-5.66%)    03-28 16:00
Open: 3.1
High: 3.11
Volume: 648,027
  
Pre. Close: 3.18
Low: 2.9
Market Cap: 193(M)
Technical analysis
2024-03-28 4:51:44 PM
Short term     
Mid term     
Targets 6-month :  3.71 1-year :  4.33
Resists First :  3.18 Second :  3.71
Pivot price 2.8
Supports First :  2.75 Second :  2.5
MAs MA(5) :  2.95 MA(20) :  2.83
MA(100) :  2.48 MA(250) :  1.93
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  76 D(3) :  67.1
RSI RSI(14): 53.4
52-week High :  3.52 Low :  1.11
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GLYC ] has closed below upper band by 24.3%. Bollinger Bands are 17.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.11 - 3.13 3.13 - 3.14
Low: 2.86 - 2.88 2.88 - 2.9
Close: 2.97 - 3 3 - 3.03
Company Description

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Headline News

Thu, 28 Mar 2024
Is it Time to Dump GlycoMimetics Inc (GLYC) Stock After it Is Up 4.86% in a Week? - InvestorsObserver

Thu, 28 Mar 2024
GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript - Yahoo Finance

Thu, 28 Mar 2024
HC Wainwright Weighs in on GlycoMimetics, Inc.'s FY2026 Earnings (NASDAQ:GLYC) - MarketBeat

Thu, 28 Mar 2024
GlycoMimetics Full Year 2023 Earnings: US$0.58 loss per share (vs US$0.89 loss in FY 2022) - Simply Wall St

Thu, 28 Mar 2024
GlycoMimetics' (GLYC) Buy Rating Reaffirmed at HC Wainwright - Defense World

Wed, 27 Mar 2024
GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 64 (M)
Shares Float 40 (M)
Held by Insiders 3 (%)
Held by Institutions 53.5 (%)
Shares Short 1,560 (K)
Shares Short P.Month 998 (K)
Stock Financials
EPS -0.63
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.72
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -46.2 %
Return on Equity (ttm) -80.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.63
Qtrly Earnings Growth 0 %
Operating Cash Flow -35 (M)
Levered Free Cash Flow -23 (M)
Stock Valuations
PE Ratio -4.77
PEG Ratio 0
Price to Book value 4.16
Price to Sales 0
Price to Cash Flow -5.5
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android